Semaglutide, marketed as Wegovy, represents a new era in obesity treatment, showing significant weight loss and health benefits. However, a recent JAMA Network Open analysis reveals a troubling trend: most patients stop taking these medications within two years. This discontinuation often leads to weight regain and loss of associated health improvements. The dynamics of obesity and health are intricate, with evidence suggesting many can be overweight yet healthy. Despite cardiometabolic advantages, stopping semaglutide can trigger a return of hunger and health declines, particularly among those without type 2 diabetes.
The popular weight-loss drug semaglutide shows effectiveness for obesity treatment, but many patients stop using it within two years, reversing weight loss benefits.
The relationship between health and weight is complex, indicating that with growing evidence, many overweight individuals may still be considered healthy.
Collection
[
|
...
]